Emkay Global Financial Services has raised its target price for Park Medi World to ₹375 per share from ₹350, maintaining a 'Buy' rating on the stock.
The upward revision follows the hospital operator's strong first-quarter results for the fiscal year ending March 2027, which showed robust top-line and bottom-line expansion.
Park Medi World reported a 19% year-on-year increase in revenue for the June quarter, while profit after tax surged by 31%.
Park Medi World reported a 19% year-on-year increase in revenue for the June quarter, while profit after tax surged by 31%.
The improved financial performance has prompted the brokerage to see over 32% upside potential from current levels, signaling confidence in the company's near-term growth trajectory.
The analyst note adds to a broader wave of positive sentiment surrounding Indian healthcare stocks.
Park Medi World has been identified by other market participants, including Choice Institutional Equities, as a key beneficiary of the ongoing sector rotation.